Desferal, deferoxamine

CareFirst Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: _____ **Date**: _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Referring Provider Info: ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Rendering Provider Info: ❑ **Same as Referring Provider** ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____*kg*

Patient Height: _____*cm*

Please indicate the place of service for the requested drug:

❑ *Ambulatory Surgical* ❑ *Home* ❑ *Off Campus Outpatient Hospital*
❑ *On Campus Outpatient Hospital* ❑ *Office* ❑ *Pharmacy*

What is the ICD-10 code? _____

Which drug is being prescribed?
❑ Desferal ❑ deferoxamine ❑ Other _____

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Desferal, deferoxamine SGM 1620-A – 05/2025.

Criteria Questions:

1. What is the diagnosis?

❒ Transfusional iron overload in chronic anemia, *Continue to 2*

❒ Aluminum toxicity in a patient undergoing dialysis, *Continue to 5*

❒ Hereditary hemochromatosis, *Continue to 7*

❒ Other, please specify _____, *No further questions*

2. Is the patient currently receiving treatment with the requested drug?
❒ Yes, *Continue to 3*
❒ No, *Continue to 4*

3. Is the patient experiencing benefit from therapy as evidenced by a decrease in serum ferritin levels as compared to pretreatment baseline? ***ACTION REQUIRED***: If Yes, attach supporting laboratory report or chart notes with current serum ferritin level.
❒ Yes, *No Further Questions*
❒ No, *No Further Questions*

4. Is the patient's pretreatment serum ferritin level consistently greater than 1000 mcg/L? ***ACTION REQUIRED***: If Yes, attach supporting laboratory report or chart notes with pretreatment serum ferritin level.
❒ Yes, *No Further Questions*
❒ No, *No Further Questions*

5. Is the patient currently receiving treatment with the requested drug?
❒ Yes, *Continue to 6*
❒ No, *No Further Questions*

6. Is the patient experiencing benefit from therapy as evidenced by decreased serum aluminum concentrations and/or symptomatic improvement (e.g., neurological symptom improvement, decreased bone pain)?
❒ Yes, *No Further Questions*
❒ No, *No Further Questions*

7. Is the patient currently receiving treatment with the requested drug?
❒ Yes, *Continue to 8*
❒ No, *Continue to 9*

8. Is the patient experiencing benefit from therapy as evidenced by a decrease in serum ferritin levels as compared to pretreatment baseline?
❒ Yes, *No Further Questions*
❒ No, *No Further Questions*

9. Has the patient had an unsatisfactory response to phlebotomy?
❒ Yes, *No Further Questions*
❒ No, *Continue to 10*

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Desferal, deferoxamine SGM 1620-A – 05/2025.

10. Is phlebotomy not an option for the patient (e.g., poor venous access, poor candidate due to underlying medical disorders)?
❒ Yes, *No Further Questions*
❒ No, *No Further Questions*

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X_____
Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Desferal, deferoxamine SGM 1620-A – 05/2025.